Coya Therapeutics Inc (COYA)

May 16, 2025, 10:53 AM EDT - 1 day ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 8:00 AM EDT - 4 days ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 8, 2025, 8:15 AM EDT - 9 days ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 5:00 AM EDT - 9 days ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Apr 25, 2025, 11:27 AM EDT - 22 days ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 24, 2025, 8:15 AM EDT - 23 days ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 21, 2025, 9:51 AM EDT - 26 days ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 1, 2025, 8:15 AM EDT - 6 weeks ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Mar 26, 2025, 8:15 AM EDT - 7 weeks ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 18, 2025, 8:15 AM EDT - 2 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Feb 25, 2025, 8:15 AM EST - 2 months ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 7, 2025, 5:17 PM EST - 3 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 1:53 PM EST - 3 months ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 6, 2025, 1:30 PM EST - 3 months ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 8:00 AM EST - 3 months ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 4, 2025, 8:15 AM EST - 3 months ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 8:15 AM EST - 4 months ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Dec 18, 2024, 8:15 AM EST - 5 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Nov 25, 2024, 8:15 AM EST - 6 months ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 19, 2024, 8:15 AM EST - 6 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Nov 6, 2024, 8:00 AM EST - 6 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 1, 2024, 8:15 AM EDT - 7 months ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Oct 31, 2024, 10:31 AM EDT - 7 months ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 29, 2024, 2:36 PM EDT - 7 months ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 6:41 AM EDT - 7 months ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:30 AM EDT - 7 months ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Oct 28, 2024, 8:00 AM EDT - 7 months ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Oct 23, 2024, 4:05 PM EDT - 7 months ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 7 months ago

Coya Therapeutics Announces $10.0 Million Private Placement

Oct 13, 2024, 4:17 AM EDT - 7 months ago

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 8, 2024, 9:15 AM EDT - 7 months ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Sep 24, 2024, 8:15 AM EDT - 8 months ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Sep 16, 2024, 8:15 AM EDT - 8 months ago

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Sep 3, 2024, 8:15 AM EDT - 9 months ago

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Aug 19, 2024, 9:00 AM EDT - 9 months ago

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Aug 12, 2024, 8:00 AM EDT - 9 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Aug 2, 2024, 8:15 AM EDT - 10 months ago

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

Jul 31, 2024, 8:15 AM EDT - 10 months ago

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jun 20, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Jun 11, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Jun 10, 2024, 2:55 PM EDT - 1 year ago

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Jun 3, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

May 28, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

May 23, 2024, 3:40 PM EDT - 1 year ago

Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment

May 22, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

May 20, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)

May 9, 2024, 4:10 PM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

May 1, 2024, 6:45 AM EDT - 1 year ago

Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases

Apr 26, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Apr 22, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit